| Hepatocellular carcinoma (HCC) is one of the most common tumors in china and its prognosis is poor, leading to patients die within 6-20 months. Current treatment is comprehensive therapy principle based on the main surgical operation, non-surgical means including local oncotherapy, radiotherapy, chemotherapy and biological therapy. Although liver transplantation technology becomes more mature, it also mainly applies to the early stage patients of HCC and prognosis is poor for advanced sufferer. The means can't widely benefit to the patient because of high cost and donor shortage. People have been exploring more effective drugs and methods to treat HCC.Decorin (DCN) is a major component of extracellular matrix, belonging to a small leucine-rich proteoglycan gene family (SLRP). A large number of studies in vitro and in vivo confirm that DCN can inhibit proliferation of a variety of tumor cells. Its mechanisms of inhibiting tumor cells are: (1) DCN can combine with and inhibit the biological activity of TGF-βto reduce the tumor progression and metastasis. (2) The cell cycle can be adjusted by DCN to increase the number of G1 phase cells, S phase cells significantly decrease,so proliferation of tumor cells are inhibited. (3) DCN can induce tumor cell apoptosis. Thus, DCN may serve as a new therapeutic target of HCC. It has important significance to understand DCN deeply for the prevention and treatment of HCC.AimTo investigate the expressions of DCN in tissues of HCC and its role mechanism on the proliferation of HuH7 cell line in vitro. The purpose of the study is to approach the relationship between DCN and HCC in occurrence and development,as well as providing a theoretical basis of new gene therapy for HCC.Methods1. Immunohistochemistry (SP) was used to detect DCN protein expressions in 16 samples of normal hepatic tissues, 20 samples of hepatic cirrhosis tissues and 30 samples of HCC tissues and relative paracancerous tissues. The positive expression rates and optical density values were used to analysis results with semiquantitative and quantitative ways.2. HuH7 hepatoma carcinoma cells were cultured with DCN in different concentration (0,25,50,75,100,125,150,200ng/ml) for different time(12,24,48,72,96 h and 2W). Cell activities were studied by MTT and clone test. The changes of cell cycle and apoptosis were analyzed by Flow Cytometry (FCM).Results1. Cirrhosis tissues and paracancerous tissues showed strong expression of DCN, the positive expression rates and the average optical density (OD) values were respectively 55%,73.3% and 0.2357±0.0396, 0.2983±0.1990; Weak DCN immunoreactivity was found in normal hepatic tissues and HCC tissues, the rates and values were respectively 0%, 10% and 0.1394±0.0072 and 0.1589±0.0115. DCN can strongly express in both hepatic cirrhosis tissues and relative paracancerous tissues, weakly express in HCC tissues and normal hepatic tissues.2. The inhibition effect of DCN on HuH7 cellular proliferation shows dose and time dependence. After DCN acting on HuH7 cells,the cell cycle was adjusted, G1 phase cells were obviously increased, S phase cells were significantly reduced, G2 phase cells had no obvious changes, it suggested that DCN may be delayed tumor cells transition from G1 to S phase. When DCN roles on HuH7 cells,the rate of cells apoptosis increases.ConclusionsDCN could take negative effects during the development of HCC. DCN inhibited the proliferation of HuH7 cells in vitro and effect of inhibition had a time and dose dependent relationship. DCN could block cell cycle at G1 phase. Apoptosis of hepatocarcinoma cells could be efficiently induced by DCN. DCN could inhibit proliferation of hepatoma carcinoma cell through regulating cell cycle and inducing apoptosis of cell in vitro. DCN will become a new ideal target drug of gene therapy for HCC.
|
PDF Full Text Request